Advanced Search
HAN Zhi-gang, SHAN Li, LIU Chun-ling. Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2007, 34(05): 336-339. DOI: 10.3971/j.issn.1000-8578.1706
Citation: HAN Zhi-gang, SHAN Li, LIU Chun-ling. Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2007, 34(05): 336-339. DOI: 10.3971/j.issn.1000-8578.1706

Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance

More Information
  • Corresponding author:

    SHAN Li

  • Received Date: March 29, 2006
  • Revised Date: July 24, 2006
  • Objective  To detect the expression of serum glutathione S-t ransferase-π ( GST-π) level in patients with NSCLC, and to investigate it s clinical significance. Methods  GST-π levels in serum of 46 patients with NSCLC, 19 patients with benign lung diseases and 60 health subjects were detected with ELISA. Forty-six NSCLC patients were given 2 cycles of NVB + DDP chemotherapy and clinical response was evaluated. Results  The mean serum GST-π level was significantly higher in patient s with NSCLC than in those with benign lung disease and health subject s ( P < 0. 05) . Twenty-five of 46 patients with NSCLC (54. 34 %) showed elevated serum GST-π levels above a cutoff value of 166. 14 ng/ml (mean +two standard deviations in 60 healthy control subjects) . The positive rate was significantly higher in patients with NSCLC than in those with benign lung disease 36. 84 % and heavy subjects 3. 33 % ( P <0. 05) . The positive rate of serum GST-π were 57. 14 % in squamous cell carcinoma and 52. 00 % in adenocarcinoma ( P > 0. 05) . No correlation was observed between the GST-πlevel and stage, sex, pathohistology. Of the 46 patient s treated with NVB + DDP chemotherapy, 19 patients responded to chemotherapy (overall response rate, 41. 30 %) . For the 25 patients with positive GST-πexpression, 5 patients responded to chemotherapy, response rate was 20 %. In the 21 patient s with negative GST-πexpression, 14 patients responded to chemotherapy, respone rate was 66. 67 %. This difference was statistically significant ( P < 0. 05) . Conclusion  The serum GST-π level may be a valuable tumor marker for NSCLC, There was no correlation between expression of serum GST-π and stage, sex, pathohistology. The response rate of NSCLC patients with GST-π-negative expression was higher than those with GST-π-positive. GST-2π may be a useful predictor of chemotherapy response.
  • Related Articles

    [1]ZHUANG Jinman, LU Wanting, HUANG Yuxiu, HU Zhijian, LIN Zheng, HE Fei. Risk Factors of Lymph Node Metastasis in Early-stage Cervical Cancer Patients and Build of A Nomogram Prediction Model[J]. Cancer Research on Prevention and Treatment, 2019, 46(1): 50-54. DOI: 10.3971/j.issn.1000-8578.2019.18.0942
    [2]SUN Ronghao, LI Chao, FAN Jinchuan, WANG Shaoxin, WANG Wei, LIU Kun, LAN Xiaojiao, HE Yuxin. Relationship of Tumor Location and Other Clinicopathological Features with Differentiated Thyroid Cancer with Lymph Node Metastasis[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 993-997. DOI: 10.3971/j.issn.1000-8578.2014.09.009
    [3]YANG Runxiang, LIU Lin, MA Fei, Qian Haili, YANG Fang. Correlation between Expression of CCR7, D2-40 and Lymphatic Metastases in Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016
    [4]Zhu Yan, Yang Qichang, Liu Hongbin, Liu Manhua, Zhang Xiaojuan, Shen Yi. Expression of D2-40 and survivin in Cervical Carcinoma and Their Relation to Prognosis[J]. Cancer Research on Prevention and Treatment, 2012, 39(03): 307-311. DOI: 10.3971/j.issn.1000-8578.2012.03.016
    [5]YANG Run-xiang, REN Hong-xian, DUAN Lin-can, LUO Chun-xiang, LI Mei, LIU Lin. Relationship between D2-40 and CCR7 Expression and lymph Lymph Node Metastasis in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 921-925. DOI: 10.3971/j.issn.1000-8578.2011.08.017
    [6]SONG Ping-ping, ZHANG Wei-di, SUN Xue-mei, GUO Hong-bo, LIU Shu-guang, ZHANG Bai-jiang. Analysis of Metastasis of Thoracic Mediastinal Lymph Nodes in 63 Patients with Cardiac Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(07): 791-792. DOI: 10.3971/j.issn.1000-8578.2011.07.017
    [7]ZENG Jin-yan. A Meta Analysis of Relationship between COX-2 Expression and Lymph Node Metastasis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 584-587. DOI: 10.3971/j.issn.1000-8578.2011.05.028
    [8]DON G Li, L I Weiping, YAN Wenjing, WU Suxiang. Relationship between Expression of VEGF2D and MLD and Lymph Node Metastasis in En2 dometrial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(12): 885-887. DOI: 10.3971/j.issn.1000-8578.1921
    [9]Yiskandaer, ZHANG Jian-qing, WANG Hai-feng, ZHANG Jin-rong, Aheli. Lymph Node Metastasis Rate and Metastasis Direction of Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(02): 143-145. DOI: 10.3971/j.issn.1000-8578.3319
    [10]PEI Feng, FENG Mao-hui, YANG Guo-Liang, et al. The Relationship Between the Expression of nm23-H1 and Lymph Node Metastasis in Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2000, 27(05): 385-386. DOI: 10.3971/j.issn.1000-8578.192

Catalog

    Article views (2202) PDF downloads (530) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return